A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

PHASE4RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
AgingInfluenza VaccineDendritic CellVaccine Response
Interventions
BIOLOGICAL

Flu Vaccine (Year 1)

Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.

BIOLOGICAL

Flu Vaccine (Year 2)

Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.

BIOLOGICAL

Flu Vaccine (Year 3)

Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.

Trial Locations (1)

06030

RECRUITING

UConn Health, Center On Aging, Farmington

All Listed Sponsors
collaborator

UConn Health

OTHER

collaborator

Icahn School of Medicine at Mount Sinai

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Chicago

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

The Jackson Laboratory

OTHER